Shares of Moderna, Pfizer and BioNTech traded lower on the news given that boosters were their key to an annual “cash cow” business.
The scientists’ assessment was based on a wide range of real-world observational studies as well as data from clinical trials before the vaccines were approved. “None of the studies has provided credible evidence of substantially declining protection against severe disease,” the authors wrote.
The FDA scientists involved were Marion Gruber, who leads the FDA’s Office of Vaccines Research and Review, and her deputy Philip Krause. Both recently announced their plans to step down later this year. Now it’s pretty clear that they’re perhaps doing so to oppose the booster jab rollout.
The WHO has urged against broad use of boosters, saying it would make better public-health sense to focus on immunizing those who haven’t gotten any shots yet whether because of anti-vaccine sentiment in countries with ample reserves, or because they live in places with little access to shots.
“Even if boosting were eventually shown to decrease the medium-term risk of serious disease, current vaccine supplies could save more lives if used in previously unvaccinated populations,” the authors wrote. What’s more, boosters could lead to even more harmful side effects in the population, a phenomenon which isn’t well understood, even as cases of heart inflammation have increasingly been tied to mRNA vaccines.
Readers can find the full summary below: